XML 28 R18.htm IDEA: XBRL DOCUMENT v3.25.3
Loans Payable
9 Months Ended
Sep. 30, 2025
Loans Payable  
Loans Payable

12. Loans Payable

As a result of the Acquisition of VCN, the Company acquired interest-free or below-market interest rate loans (0%-1%) extended by Spanish governmental institutions of Ministerio de Ciencia, Innovacion y Universidades (RETOS loan) and ACC10 Generalitat de Catalunya (NEBT loan). The maturities of these loans are between 2024 and 2028. As a result of the Acquisition, the Company maintains a restricted cash collateral account of $46,000 relating to the RETOS loan, which is reflected as a non-current asset on the balance sheet.

During September 2024, the Company announced that its THERICEL project had been awarded €2.28 million (approximately $2.54 million) from the National Knowledge Transfer Program of the Spanish government’s Ministry of Science, Innovation & Universities to support a collaboration between the Company and the Universitat Autònoma de Barcelona (“UAB”) to advance the Company’s THERICEL suspension cell platform for the clinical manufacture of adenovirus- and adeno-associated virus (“AAV”) therapies. Under the award, the Company (via its wholly owned subsidiary, Theriva Biologics SL) received an unsecured loan (the “Loan”) of €1.3 million (approximately $1.4 million) as a lump sum payment on January 17, 2025 which bears interest at a rate of 4.015% and is to be repaid over 7 years commencing three years from the date of award.

    

September 30, 2025

    

September 30, 2025

December 31, 2024

    

December 31, 2024

Current

Non-current

    

Current

Non-current

 

  

 

  

 

  

 

  

NEBT Loan

9

$

9

7

$

16

RETOS 2015

48

37

54

76

THERICEL Loan

1,608

$

57

$

1,654

$

61

$

92

12. Loans Payable (continued)

A maturity analysis of the debt as of September 30, 2025 is as follows (amounts in thousands of dollars):

2026

    

$

57

2027

 

35

2028

 

11

2029

 

69

2030

232

Thereafter

1,307

Total

 

$

1,711